Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with Cystic Fibrosis by Hickey, Helen R et al.
RESEARCH Open Access
Feasibility study to inform the design of a
randomised controlled trial to eradicate
Pseudomonas aeruginosa infection in individuals
with Cystic Fibrosis
Helen R Hickey
1, Ashley P Jones
1, Warren Lenney
2, Paula R Williamson
1, Rosalind L Smyth
3*
Abstract
Background: There are controversies about the most effective treatment to eradicate first growth of Pseudomonas
aeruginosa (P aeruginosa) from the lower airways of patients with cystic fibrosis (CF). UK guidelines recommend oral
treatment, but some advocate intravenous (IV) treatment. The objective of this study was to assess the feasibility of
conducting a randomised controlled trial comparing two treatment strategies to eradicate Pa e r u g i n o s ain CF patients.
Methods/Principal Findings: Two surveys were conducted. Survey [1] included clinicians who were responsible
for the treatment of individuals with CF, to assess their clinical practice, opinions and numbers of potentially
eligible patients. Survey [2] included adults and young people aged 13 years or more with CF and parents of
children with CF aged less than 13 years, identified at six UK CF centres, who fulfilled eligibility criteria for the
proposed clinical trial, to assess their views about the interventions and their willingness to participate in the trial.
Generally clinicians treat first or new growth of P aeruginosa with oral antibiotics, but 90% reported that they
would consider IV treatment of first isolation of P aeruginosa. 74% of clinicians would consider recruiting their
patients and 45% of consumers would consider entry for themselves or their children into a trial comparing oral
with intravenous antibiotics. The median rate per annum for first or new growths of P aeruginosa in adults was 3%
(range 1% to 9%) and in children was 10% (range 3% to 23%). If the trial was conducted across the UK, with a
consent rate of 45%, then the number of eligible patients per annum who would be willing to take part in a study
would be approximately 41 adults and 203 children.
Conclusions: This work demonstrates the importance of feasibility studies in preparation for multicentre clinical
trials. It confirmed the uncertainty amongst clinicians and patients about the clinical question, enabled assessment
of the number of potentially eligible patients, the proportion of patients and clinicians prepared to participate and
aspects of trial design which might encourage this. It showed that a clinical trial was feasible, but only if patients
were recruited from across United Kingdom.
Introduction
Cystic fibrosis (CF) is the most common life-limiting
inherited disease in Caucasian populations, where the
prevalence is around one in 2000 live births. The pri-
mary cause of death in people with CF is respiratory
failure resulting from chronic pulmonary infection[1].
Acquisition of chronic infection of the airways with
Pseudomonas aeruginosa (P aeruginosa) has been consis-
tently shown to be associated with shortened survival
[2,3]. Because of this, in most CF centres, identification
of P aeruginosa from the lower airways of a CF patient,
previously considered free of this infection, is treated
with therapy designed to eradicate the organism[4].
However evidence for the overall effectiveness of this
strategy, or the optimal treatment regimen to achieve
this outcome is lacking[5].
In the UK, when a patient has a first respiratory culture
in which P aeruginosa is isolated, the UK Cystic Fibrosis
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dication therapy in the form of nebulised colistin and oral
ciprofloxacin for three weeks, following which cultures
should be repeated; if the repeat culture is negative no
further colistin or ciprofloxacin is given[6]. However,
some clinics continue colistin and ciprofloxacin for three
months, in line with practice in Denmark[4]. Whilst
acknowledging the lack of evidence, the guidelines present
a number of alternatives for management, should this
initial treatment be unsuccessful in eradicating Pa e r u g i -
nosa; these include intravenous therapy, for two weeks,
with two anti-pseudomonal antibiotics.
T h em o s tr e l i a b l em e t h o do fa d d r e s s i n gt h el a c ko f
evidence would be to conduct a randomised controlled
trial (RCT), using the current standard protocol of oral
ciprofloxacin plus nebulised colistin compared with
intravenous anti-pseudomonal antibiotics, both groups
receiving, in addition, nebulised colistin for three
months. IV therapy is invasive, thus there are concerns
about the acceptability of this trial to patients with CF
and, for children, their parents. Clinicians may also not
be in equipoise about this treatment and because CF is
a relatively rare disease, it may be impossible to recruit
adequate numbers of patients with CF, who fulfil the
inclusion criteria, to a clinical trial. A major UK funding
body, the NIHR Health Technology Assessment Pro-
gramme, were considering commissioning the proposed
trial and commissioned this feasibility study to:
￿ Conduct a survey of current practice for treatment
of P aeruginosa infection.
￿ Conduct a survey of attitudes of clinicians, parents
(and patients if old enough) towards the proposed
RCT.
￿ Estimate the number of cystic fibrosis patients who
are currently not colonised with Pa e r u g i n o s aand
the number likely to become positive each year (and
therefore eligible for the proposed RCT).
Methods
A consortium of Directors from five UK CF centres and
staff from the Medicines for Children Research Network
Clinical Trials Unit (MCRN CTU) collaborated to
design survey questionnaires relevant to two target
groups; CF clinicians and consumers who were potential
participants for the proposed RCT, or parents of poten-
tial participants. Prior to commencing, confirmation was
received from the UK Central Office for Research Ethics
Committees (now National Research Ethics Service) that
ethical approval was not required.
In September 2006, all UK CF centre clinicians (63) who
were registered with the UK CF Trust were contacted and
invited to complete a questionnaire (Additional file 1).
Individuals were initially approached by e-mail in the first
instance and were invited to complete an electronic sur-
vey, within three weeks, after which time electronic access
was disabled. Those who failed to complete and submit an
electronic questionnaire in three weeks were sent a paper
copy and asked to complete it. All respondents were anon-
ymous to the study team, however a unique code assigned
by the UK CF Trust to questionnaires completed online
enabled the population type (adult or paediatric) to be
reported (this information was not available for those
questionnaires that were received by post). The question-
naire provided details about the proposed clinical trial,
including the eligibility criteria for patients, the interven-
tions in the two treatment regimens and two suggested
primary outcome measures: time to next growth of P aer-
uginosa following successful eradication and eradication of
P aeruginosa from any lower respiratory tract culture over
a two year period. The questionnaire asked about clini-
cians’ current management of first or new isolation of P
aeruginosa, their views about the certainty of evidence for
these strategies and whether they would be prepared to
recruit patients to the proposed trial. Finally, to provide an
estimate of the number of potentially eligible patients pre-
senting per annum in the UK, clinicians were asked about
the population size of their CF clinic, the number of
patients who have never had a lower respiratory tract cul-
ture or who are not colonised with P aeruginosa and how
many patients present with first or new growths of P aeru-
ginosa per annum.
In parallel with the clinician survey, the consumer
questionnaire was developed. This delivered a descrip-
tion of the proposed trial in a similar format to that
which would be used in a patient information leaflet to
inform consent. A draft of the consumer questionnaire
was opportunistically discussed in clinic with children,
parents and the multidisciplinary CF team at Alder Hey
Children’s Foundation Trust, Liverpool and revised to
reflect comments.
Patients and parents of children who would fulfil the
eligibility criteria for the proposed trial were invited to
complete the consumer survey (Additional file 2). These
were either patients with CF who were ≥ 13 years of age
or the parent of a child with CF aged < 13 years. In addi-
tion, they must either (a) never have isolated P aeruginosa
from a respiratory culture or (b) have previously isolated P
aeruginosa, undergone eradication therapy and have had
at least three consecutive negative respiratory cultures
over a six month period to indicate eradication therapy
had been successful. The target recruitment for the consu-
mer survey was at least 50 parents and 50 young people or
adults with CF. Consumer questionnaires were delivered
to six participating UK CF centre sites, for distribution in
routine outpatient clinics between 24 July and 30 October
2006. These centres were purposively sampled, based
upon the judgment of the lead investigators, as being
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would ultimately be recruitment centres for inclusion in
the definitive trial. These centres were able to provide tar-
get recruitment of adults and children with CF in this
time period, with clinics typically seeing 15 to 20 patients
per week. Adults and young people aged 13 years or more
with CF and parents of children with CF aged less than 13
years who would fulfil eligibility criteria for the proposed
clinical trial were approached consecutively as they
attended the appropriate clinic until target study accrual
was reached. Questionnaires were generally distributed
and collected by clinical nurse specialists during these out-
patient clinics, with participants encouraged to complete
and return the survey before leaving the hospital. Partici-
pants were asked to complete the questionnaire once only,
and only one questionnaire was completed per family unit.
Respondents were provided with envelopes within
which to seal completed surveys as an assurance that
their answers remained confidential. The nurse specia-
lists were responsible for returning the sealed envelopes
to the MCRN CTU, maintaining anonymity of respon-
dents. The questionnaires explored consumer attitudes
to the envisaged RCT, enquired how important they
b e l i e v e dt h i st r i a lt ob ea n dw h e t h e rt h e yw o u l db e
happy to be randomised, or have their child randomised,
to either group, following an explanation of the treat-
ment procedures involved (e.g. intravenous access). As a
check against the survey eligibility criteria, participants
were asked whether they (or their child) had isolated P
aeruginosa twice or more in the last 6 months.
Results from categorical data were presented as per-
centages in tables (including numerator and denomina-
tor), continuous data were presented as medians and
ranges. No formal statistical testing was carried out on
the data. To estimate the potential number of partici-
pants that would be eligible for a future trial, the med-
ian rate per annum of first or new growths was
calculated from the clinician questionnaires and applied
to the patient populations provided by the UK CF
Trust, applying an estimated consent rate (based on
consumer responses) to this figure would then give the
potential number of eligible participants for the pro-
posed trial.
Results
For the clinician survey 63 clinicians from 57 CF centres
throughout the UK were approached and 42 clinicians
returned survey questionnaires, 33 online (from 31 inde-
pendent centres) and an additional 9 received via postal
survey following termination of the online access. This
provided an overall response rate from clinicians of
70%. The majority of clinicians reported that they would
treat a new isolation of Pa e r u g i n o s ain a given indivi-
dual in the same way that they treated their first ever
isolation, routinely favouring oral ciprofloxacin in com-
bination with nebulised colistin (Table 1). However, four
clinicians reported that they would routinely treat first
presentation of P aeruginosa with IV antibiotics in com-
bination with colistin and 38 clinicians who completed
the survey indicated that they would consider treatment
Table 1 Reported treatment practice of clinicians in specialist CF centres
Yes No
Is the treatment of a new growth of P aeruginosa the same as the first ever isolation
a 33/41
(80%)
8/41
(20%)
Routine treatment of patients who present with their first growth
of P aeruginosa
b
Oral ciprofloxacin for 3 weeks and nebulised colistin
for 3 months
21/29
(72%)
8/29
(28%)
Oral ciprofloxacin and nebulised colistin for 3 months 10/22
(45%)
12/22
(55%)
IV antibiotics for 2 weeks and nebulised colistin for 3
months
4/18(22%) 14/18
(78%)
Other 9/22 (41%) 13/22
(59%)
Is the first or a new P aeruginosa isolation ever treated with IV antibiotics and nebulised colistin rather than oral
ciprofloxacin and nebulised colistin?
38/42
(90%)
4/42
(10%)
Likely to treat first or new growth of P aeruginosa with IV
antibiotics when
b
The patient is clinically unwell 35/35
(100%)
0/35 (0%)
The patient has had a previous culture of P
aeruginosa
13/24
(54%)
11/24
(46%)
The patient has reduced lung function 28/31
(90%)
3/31
(10%)
Other reason 14/21
(67%)
c
7/21
(33%)
a1 respondent did not complete this question
bNo responses were compulsory for this question and clinicians were able to select more than one option
c 5 other reasons related to clinical deterioration; 3 to ciprofloxacin resistance and 2 to patient preference/adherence
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tics under certain circumstances, particularly if the
patient was clinically unwell.
Clinicians’ perceptions of the available evidence for
oral antibiotic treatment, in combination with nebulised
colistin, and their views on the efficacy of IV versus oral
antibiotics as an eradication therapy were explored.
When asked how good they thought the evidence was
to support the treatment of first or new growth of P
aeruginosa with oral ciprofloxacin and nebulised colistin,
n o n et h o u g h ti tt ob ee x c e l l e n t ,4 6 %t h o u g h ti tt ob e
good, 42% fair, 10% poor and 2% replied ‘don’tk n o w ’.
Over half (21 [53%]) of clinicians responded ‘don’t
know’ when asked to express an opinion about whether
IV antibiotics are more effective than oral ciprofloxacin
(each in combination with nebulised colistin for a period
of three months) in eradicating first or new growth of P
aeruginosa; 11 (27%) thought they were more effective
a n de i g h t( 2 0 % )t h a tt h e yw e r en o t .T w e n t yn i n e( 7 4 % )
of the 39 clinicians who answered the question were
prepared to recruit patients to the proposed trial, with
only two (5%) stating that they would not do so, due to
their own perception that oral treatment is effective.
Eight respondents (21%) were unsure that they would
recruit patients into the proposed trial and three respon-
dents did not answer this question. Clinicians were
asked for general comments about the design of the
trial and whether they would suggest alternative primary
outcome(s). A variety of suggestions were made, but
there was overall agreement that the primary outcome
should reflect growth of Pa e r u g i n o s afrom lower
respiratory tract cultures at some time point.
The median number of patients that were registered
from the 31 independent centres that replied was 125
(range 35 to 380). The median percentage of patients
who had never grown Pa e r u g i n o s awas 26% (range 6%
to 63%). The median rate per annum for the number of
first or new growths of Pa e r u g i n o s ain adults was 3%
(range 1% to 9%) and in children was 10% (range 3% to
23%).
106 consumers from six UK CF centres completed
and returned survey questionnaires. Centres did not
report on the number of consumers who refused to
accept a questionnaire when offered, therefore it is not
possible to draw assumptions about potential bias which
might have occurred as a result of refusals, however of
those questionnaires issued only one was returned not
completed to researchers. Sixty-eight (64%) of the con-
sumer surveys were received from exclusively paediatric
centres and 60 (56%) of consumer respondents were
parents. Median age of the patient with CF was 10 years
(Range 1 to 51 years); 62 (58%) were female. Forty
(37%) patients had never grown Pa e r u g i n o s afrom a
cough swab or sputum sample and two did not respond
to the question. Of the 64 respondents who had
reported previous infection with Pa e r u g i n o s a ,2 2( 3 4 %
of respondents) had experience of being treated for a
first or new growth with intravenous (IV) antibiotics
plus colistin (Table 2).
When asked whether in their opinion oral or IV anti-
biotics would be better at eradicating P aeruginosa,
about half of all consumers responded that they did not
know (Table 3). Forty-five respondents (30 parents), out
of 99, indicated that they would consider entry into the
proposed RCT. The main reason given by consumers,
who answered no to this question, was that they did not
wish to participate in a trial. Other reasons included
constraints on time, that they did not want unnecessary
hospital admission and that they would not want to
have IV treatment; two explicitly stated that they did
not like needles. The main reason stated by consumers
who would consider trial entry was to help in future
research. Eighteen of the affirmative respondents had no
previous experience of P aeruginosa infection.
The total adult population reported by clinicians who
responded to the survey was 1210 (9 centres) and the
total paediatric population was 2676 (20 centres). Two
responses were received from centres with mixed adult
and paediatric populations for whom we could not
derive the separate population sizes, therefore they are
Table 2 Treatment experiences of 64 participants who had previously isolated Pseudomonas from a cough swab or
sputum sample.
Yes No Don’t know
Have Isolated P. aeruginosa ≥ 2 times in last 6 months
a 5/63 (8%) 55/63 (87%) 3/63 (5%)
Treated for first or new growth with oral ciprofloxacin plus colistin 53/64 (83%) 6/64 (9%) 5/64 (8%)
Treated for first or new growth with IV antibiotic plus colistin 22/64 (34%) 37/64 (58%) 5/64 (8%)
Treated for first or new growth with IV antibiotic plus colistin
Yes No Don’t know
Treated for first or new growth with oral ciprofloxacin plus colistin Yes 20 32 1
No 141
Don’t know 113
a1 respondent did not complete this question.
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lation for the proposed trial we applied the median rate
p e ra n n u mo ff i r s to rn e wg r o w t h so fPa e r u g i n o s ato
each of these populations individually using the respec-
tive rates presented above (3% and 10% for adults and
children respectively), which provided an estimate of 30
adults and 262 children per annum, from these centres,
who would be eligible for recruitment. The UK CF
Trust provided data for patients from 21 adult centres,
27 paediatric centres and two centres with both children
and adults, who were able to provide figures for both
groups. Applying the above rates to the population data
provided by the UK CF Trust provides a conservative
estimate of adults and children of 91 and 450 respec-
tively per annum. If the consent rate was estimated to
be 45% then the number of eligible patients per annum
who would be willing to take part in a study, as pre-
sented in our survey would be approximately 41 adults
and 203 children per annum.
Discussion
The key finding from this feasibility study is that,
although management of first or new presentations of P
aeruginosa isolations in the UK is generally in line with
UK CF Trust guidelines[6], there is considerable uncer-
tainty amongst clinicians about whether the systemic
therapy used in this regimen should be with IV or oral
anti-pseudomonal antibiotics. Reflecting this doubt, all
clinicians stated that they would consider using IV anti-
biotics in specific circumstances. When consumers were
asked their views about the effectiveness of IV or oral
treatment, they showed even greater uncertainty, with
only a minority stating that one treatment was “defi-
nitely” better or worse.
The majority of clinicians, who completed this survey,
indicated that they would be prepared to consider enter-
ing patients under their care into an RCT investigating
these alternative treatments.T h e r ew a sa l s or e a s o n a b l e
support for such a trial in the consumer population,
with 45% reporting that they would consider entry. This
study also provided important information about rea-
sons why patients may not wish to enter this trial (e.g.
potential inconvenience of hospital admission for IV
treatment), some of which should be considered in trial
design (e.g. provision of IV therapy at home, where
appropriate).
The funding body was concerned about whether, with
these estimates of clinician participation in recruitment
and the willingness of potential participants to be
enrolled in the trial, sufficient numbers could be rando-
mised to address the objectives. Therefore we estimated
the sample size of this study, based on each of the two
primary outcomes which we had proposed. For the pri-
mary outcome “time to chronic P aeruginosa infection”,
data were examined from a Danish study[4] which
reported that, over a three and a half year period, seven
of 48 (15%) CF patients with lower airways cultures of P
aeruginosa, who were treated with colistin inhalation
and oral ciprofloxacin for between three weeks and
three months developed chronic P aeruginosa colonisa-
t i o nc o m p a r e dw i t h1 9o f4 3( 7 2 % )h i s t o r i c a lc o n t r o l s .
This suggested that in the patients who were treated
with colistin inhalation and oral ciprofloxacin, chronic
infection would be prevented or delayed in 85% of
patients. To detect an increase from 85% to 90% or 95%
free of chronic infection in the IV group would require
690 or 146 per group respectively for 80% power at the
5% significance level. To estimate the sample size based
upon a primary outcome of ‘eradication of infection’,w e
estimated the initial eradication rate, using data from an
observational study [7] where the protocol used colistin
inhalation and oral ciprofloxacin achieved eradication
(three consecutive negative respiratory P aeruginosa cul-
tures and negative serum antibody titres within a six
month period) in 47/58 (81%) patients. If the initial era-
dication rate in the comparator arm is assumed to be
80% to detect an increase to 90% with IV antibiotics, for
80% power at 5% significance level, would need 219 per
group, or 263 per group allowing for a 20% dropout.
These sample size calculations should be considered in
the context of a trial which would run over at least two
years and where the total number of potentially eligible
patients in all of the UK per year was about 250.
Overall, clinical trials which have investigated routine
therapies in patients with cystic fibrosis are relatively
few and of inadequate design[8,9]. Although, a number
of recent trials have addressed the benefits of existing
therapies[10,11] and this picture is slowly improving[12],
Table 3 Consumer opinions about efficacy of P aeruginosa treatment
Definitely
better
Possibly
better
No
difference
Possibly
worse
Definitely
worse
Don’t
know
Is oral ciprofloxacin better than IV antibiotics at getting rid of
pseudomonas?
a
7 (7%) 17 (16%) 4 (4%) 19 (18%) 6 (6%) 51 (49%)
Are IV antibiotics better than oral ciprofloxacin at getting rid
of pseudomonas?
b
10 (10%) 29 (28%) 3 (3%) 5 (5%) 3 (3%) 53 (51%)
a 2 participants did not respond to this question
b 3 participants did not respond to this question
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tiveness of many widely used, expensive and often inva-
sive treatments for people with CF. CF patients and
families are generally very well informed about their dis-
ease and its treatment, but this is the first study, of
which we are aware, which has formally sought their
views about acceptability of a proposed clinical trial.
This study was conducted by staff at the MCRN Co-
ordinating Centre and CTU; one of the central princi-
ples of MCRN is that children and families should be
involved in all aspects of research which is relevant to
their needs[13,14]. Although it may be argued that con-
ducting a feasibility survey could delay the initiation of
an important RCT, exploring opinions of clinicians and
consumers in this way enables an informed decision to
be made about the acceptability and feasibility of a pro-
posed RCT. This feasibility study was conducted over a
period of approximately six months and cost around
£16,000; the time and financial requirements are mini-
mal when compared to the potential expenditure asso-
ciated with the initiation of a clinical trial that does not
recruit enough patients to answer the clinical question.
Questionnaire surveys such as these have recognised lim-
itations and every attempt was made to maintain anonym-
ity of respondents in order to obtain true opinions.
Although consumers completed questionnaires during rou-
tine clinic visits they were assured that their local team
could not access responses as they were able to return their
anonymously completed survey directly to the researchers.
Additionally, the clinician surveys were completed remotely
and anonymously. Despite this, there is a possibility that
whilst clinicians may have indicated a general willingness to
randomise their patients, they may be reluctant to do so in
specific clinical circumstances. Similarly, patients/families
previous experience of eradication therapy may influence
their responses and their willingness to participate in a trial
and these considerations are a reflection of the real life
challenges facing clinicians conducting clinical trials.
This survey indicated that it was feasible to consider
the initiation of a randomised controlled trial investigat-
ing eradication therapy to treat P aeruginosa in patients
with CF. We have reported these findings to the funders
of the feasibility study, The NIHR Health Technology
Assessment Programme, who subsequently took the
decisions to commission this trial and subsequently to
award funding to a group of investigators to run this
trial in the UK http://www.hta.ac.uk/1763.
Conclusions
This study confirmed the uncertainty amongst clinicians
and patients about the optimal way to treat first or new
isolation of Pa e r u g i n o s afrom the airways of patients
with CF and provided sound rationale for the clinical
trial. It provided an estimate of the proportions of
potentially eligible patients, of patients and clinicians
who would be prepared to participate in such a RCT
and aspects of trial design which might make it more
acceptable. This information is essential to informing
the design of the trial and whether it would be feasible,
even when conducting across the United Kingdom.
Such feasibility studies are particularly important for
trials with patients with rare diseases.
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